瑞舒伐他汀对慢性肾病患者抗炎作用的临床观察

Anti-inflammatory Effects of Rosuvastatin in Patients with Chronic Kidney Diseases

目的探讨瑞舒伐他汀对慢性肾病患者抗炎疗效。方法选取2009年11月-2010年12月90例慢性肾病患者,随机分为A、B两组,A组50例,给予瑞舒伐他汀钙10 mg/d;B组40例,给予阿托伐他汀钙10 mg/d,两组患者的年龄和性别相匹配。分别测定其治疗前及治疗后12周时血白细胞、高敏反应蛋白、纤维蛋白原、白介素-6、肿瘤坏死因子-α。结果两组治疗前各炎症指标水平差异无统计学意义(P>0.05)。与治疗前相比,两组患者治疗12周后炎症指标水平均较前明显下降(P<0.01),瑞舒伐他汀钙组比阿托伐他汀钙组炎症指标下降更为明显。结论瑞舒伐他汀可有效改善慢性肾病患者的炎症反应。

Objective To explore the anti-inflammatory effect of rosuvastatin on chronic kidney disease （CKD） patients. Methods Ninety CKD patients treated in our hospital between November 2009 and December 2010 were randomly divided into two groups. One group was given rosuvastatin calcium 10 mg/d, which the other group was given atorvastatin calcium 10 mg/d. The two groups matched in terms of age and gender. We determined blood leukocyte （WBC）, high sensitivity reactive protein （hs-CRP）, fibrinogen （FIG）, interleukin-6 （IL-6） and tumor necrosis factor-a （TNF-a） of the patients before and after treatment for 12 weeks. Results The inflammatory marker levels of both groups before treatment had no significant differenee （P^0.05）. The inflammatory marker levels of two groups after treatment for 12 weeks were significantly decreased compared with the levels before treatment （P（ 0. 01）, and rosuvastatin calcium group decreased more apparently than atorvastatin calcium group. Conclusion Rosuvastatin can improve the anti-inflammatory response in CKD patients.